Erasca · pitchdeck
Erasca | Investor Presentation Deck | 56 slides
56 pages · 5 arc beats · 2 loops
Erasca | Investor Presentation Deck | 56 slides
Erasca · 2023-08 arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
12468101214161820222426283032343638404244464850525456
Deck intelligence map
5 coverage by narrative range · generated from this deck JSON
Narrative range 27 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Problem (Identify pain) 1 slides 100% 1/1 slides 100% 1/1 slides · 6 hits — 0/1 slides
100% 1/1 slides · 2 hits — 0/1 slides
100% 1/1 slides · 3 hits 100% 1/1 slides Agitate (Make it worse) 6 slides 100% 6/6 slides 100% 6/6 slides · 29 hits — 0/6 slides
50% 3/6 slides · 4 hits 33.3% 2/6 slides 100% 6/6 slides · 13 hits 100% 6/6 slides Solution (Provide relief) 9 slides 100% 9/9 slides 100% 9/9 slides · 39 hits — 0/9 slides
22.2% 2/9 slides 55.6% 5/9 slides 100% 9/9 slides · 11 hits — 0/9 slides
Evidence & Proof 8 slides 100% 8/8 slides 100% 8/8 slides · 40 hits — 0/8 slides
62.5% 5/8 slides · 6 hits 25% 2/8 slides 100% 8/8 slides · 17 hits 75% 6/8 slides Impact & Next Steps 3 slides 100% 3/3 slides 100% 3/3 slides · 12 hits — 0/3 slides
66.7% 2/3 slides 33.3% 1/3 slides 100% 3/3 slides 100% 3/3 slides Slide inventory
56 every slide · same image gating as the playbook
01
The slide uses a high-quality stock photo to evoke an emotional connection to the company's mission.front_matter
03
The slide uses a hub-and-spoke diagram to connect the company name to three core pillars: leadership, portfolio, and financials.inspire_vision
05
The table uses a heatmap-style color coding where red indicates existing targeted therapy markets and teal indicates blue ocean opportunities.size_opportunity
06
The diagram illustrates a biological signaling pathway with specific nodes highlighted as targets for the company's therapeutic approach.present_solution
Open slide detailBeat · Solution (Provide relief)
07
The slide uses a Gantt-style visualization for clinical trial stages.plan_implementation
Open slide detailBeat · Solution (Provide relief)
08
The slide uses a biological process diagram to map drug assets to specific protein targets.present_solution
Open slide detailBeat · Solution (Provide relief)
09
The slide uses a matrix structure to map indications to benchmarks, specific drug regimens, and trial names, with a footer detailing active clinical trial collacompare_peers
Open slide detailBeat · Solution (Provide relief)
10
The chart uses a stacked bar approach to represent US and European patient counts per clinical program.size_opportunity
Open slide detailBeat · Solution (Provide relief)
11
The slide combines a biological pathway diagram (left) with a quantitative market sizing table (right).size_opportunity
Open slide detailBeat · Solution (Provide relief)
12
The kinome tree visualization (KINOMEscan) is a standard industry tool for demonstrating kinase selectivity.present_solution
Open slide detailBeat · Solution (Provide relief)
13
The slide combines a biological pathway diagram (mechanism of action) with a clinical trial summary table.show_traction
Open slide detailBeat · Solution (Provide relief)
14
Includes two waterfall plots comparing patient responses; source cited as Novartis materials.show_traction
Open slide detailBeat · Solution (Provide relief)
15
The slide highlights the poor efficacy of current SOC and suggests binimetinib as a superior alternative.frame_problem
16
Waterfall plot uses standard clinical trial terminology (PD, SD, PR). Comparison table highlights the study drug's performance against Dacarbazine and Binimetinshow_traction
17
The slide uses a before-and-after visual comparison to demonstrate clinical efficacy.illustrate_case
18
Swimmer plot visualization of clinical trial data (Trial LXH254X2102).show_traction
19
The slide highlights consistent clinical activity across two study phases, culminating in a combined ORR of 33.3%.show_traction
20
Swimmer plot visualization of clinical trial data.show_traction
21
The diagram uses a tree structure to categorize patient outcomes (off treatment vs on treatment, further broken down by SD and PR).analyze_data
22
The chart displays adverse events occurring in >=10% of patients (n=15).analyze_data
23
CoC = Cost of Care (or standard of care context); FIH = First-in-Human; PTS = Probability of Technical Success; CDP = Clinical Development Plan.plan_implementation
24
The slide uses a biological signaling pathway map to justify combination therapy strategy.present_solution
25
The diagram shows the RAS/MAPK signaling pathway. The table provides a breakdown of patient populations for specific indications.size_opportunity
27
The diagram shows the signaling pathway with specific drug targets highlighted.present_solution
28
Data shows tumor volume over time for various treatment groups including monotherapy and combinations.show_traction
29
Includes waterfall plot (left) and swimmer plot (right) with specific response rates and disease control rates.show_traction
30
Data cut 23MAR2023. Table shows frequency of specific adverse events by severity grade and dosage cohort.analyze_data
31
The slide uses a process-oriented flow to demonstrate clinical validation milestones.show_traction
32
The slide uses arrows to visually indicate performance superiority of ERAS-601 over RMC-4550.compare_peers
33
Data presented as tumor volume over time (days) with error bars representing SEM.show_traction
34
Includes RECIST 1.1 criteria reference and specific tumor measurements over time.illustrate_case
35
The table displays counts and percentages of patients experiencing specific adverse events, categorized by severity (All vs Grade >= 3).analyze_data
36
The diagram shows the EGFR signaling pathway leading to MAPK and PI3K pathways.size_opportunity
37
The slide uses a stacked bar chart to show mutation incidence and a comparison table to highlight clinical trial failures in GBM despite success in other indicaframe_problem
38
The slide uses Western blot data to demonstrate potency and a table to demonstrate pharmacokinetic superiority.present_solution
39
The chart shows a statistically significant (***) improvement in survival for the ERAS-801 group compared to the control and other standard-of-care inhibitors.show_traction
40
The slide presents four separate survival plots (HK301, GS025, HK336, GS187) comparing vehicle control to ERAS-801 treatment.show_traction
41
The slide uses a waterfall plot to show individual model responses, with a heatmap below for patient characteristics (recurrence, sex, methylation status).show_traction
42
The slide uses a table format to communicate a product development roadmap.plan_implementation
44
Features the Lorenz attractor graphic, which is a signature visual for Erasca.state_next_steps
45
The slide uses a structured comparison between preclinical and clinical assets, with a specific callout for the lead asset (Naporafenib).compare_peers
46
The diagram uses a bullseye/concentric circle metaphor to represent strategic focus areas.plan_implementation
47
The slide uses a contrast-based layout to frame the subject as a winner in a difficult therapeutic space.compare_peers
48
The slide uses western blot data to demonstrate the efficacy of ERAS-007 in a specific biological pathway context.present_solution
49
The slide uses a before-and-after imaging comparison to show clinical efficacy.illustrate_case
50
The chart displays individual patient responses categorized by dose level, with a list of specific notable responses on the right.show_traction
51
The chart displays patient-level data including cancer type, mutation, weekly dose, and response status (Partial Response, Stable Disease, Progressive Disease).show_traction
53
The slide compares various dosing schedules (QW, BID-QW, BIW) against IC90 and IC50 thresholds.analyze_data
54
The slide uses a comparison frame to position ERAS-601 against competitors like Novartis, Revolution Medicines, Jacobio, Genentech, Pfizer, and Merck.compare_peers
55
The slide uses a biological pathway diagram to illustrate the mechanism of action.present_solution
56
The slide compares two different drug candidates' PK profiles against IC50 and IC90 thresholds.analyze_data